Cenobamát v léčbě farmakorezistentní fokální epilepsie

Česká verze

Authors: J. Kočvarová
Authors place of work: Centrum pro epilepsie Brno, 1. neurologická klinika LF MU a FN u sv. Anny v Brně
Published in the journal: Cesk Slov Neurol N 2023; 86(2): 153-154
Category: Dopis redakci
doi: https://doi.org/10.48095/cccsnn2023153

Zdroje

1. SPC léčivého přípravku Ontozry. [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/ontozry-epar-product-information_cs.pdf.

2. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51 (6): 1069–1077. doi: 10.1111/j.1528-1167.2009.02397.x.

4. Chung SS, French JA, Kowalski J et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology 2020; 94 (22): e2311–e2322. doi: 10.1212/WNL.0000000000009530.

5. Krauss GL, Klein P, Brandt C et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol 2020; 19 (1): 38–48. doi: 10.1016/S1474-4422 (19) 30399-0.

6. Sperling MR, Klein P, Aboumatar S et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia 2020; 61 (6): 1099–1108. doi: 10.1111/epi.16525.

7. Sander JW, Rosenfeld WE, Halford JJ et al. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia 2022; 63 (1): 139–149. doi: 10.1111/epi.17134.